India, Oct. 28 -- electroCore, Inc. (ECOR) announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for its Quell wearable neuromodulation platform for the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN).
CIPN is a common complication of certain cancer treatments that can cause persistent pain, numbness, tingling, sensory abnormalities and impaired physical function.
The condition can continue for months or years after chemotherapy, affecting patients' daily activities and quality of life. Currently, no drugs or devices have an FDA-approved or cleared indication specifically for CIPN.
The submission is supported by clinical data from two studie...